|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
|
16258541 |
2005 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A secondary mutation, T790M, has been associated with acquired resistance but has not been shown to be sufficient to render EGFR mutant/amplified lung cancers resistant to EGFR inhibitors.
|
16906227 |
2006 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.
|
17671147 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T790M mutation is present in about half of the lung cancer patients with acquired resistance, and reported to act by increasing the affinity of the receptor to adenosine triphosphate, relative to its affinity to TKIs.
|
19096299 |
2009 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET.
|
19351834 |
2009 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de novo and acquired resistance to irreversible EGFR-TKIs in lung cancer harboring T790M mutation in EGFR.
|
20008840 |
2010 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We used five series of lung cancers: 47 non-small cell lung cancers (NSCLC) to evaluate various types of EGFR mutations, a consecutive series of 238 NSCLCs to study the sensitivity and specificity, 11 NSCLCs with both EGFR mutation and amplification to examine the spatial distribution, 32 patients treated with gefitinib to compare clinical responses, and 15 NSCLCs to explore changes associated with acquired T790M mutation.
|
20570926 |
2010 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
|
21062933 |
2010 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
|
21135146 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found that EMT developed in a lung cancer patient who had an acquired resistance to erlotinib while there were no known resistant mechanisms such as T790M and MET amplification.
|
21168239 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
|
21248300 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of low-level EGFR T790M mutation in lung cancer tissues.
|
21635547 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings indicate promising therapeutic applications of miR-7-expressing plasmids against EGFR oncogene-addicted lung cancers including T790M resistance by liposomal delivery.
|
21712475 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amplification in tumors with intrinsic and acquired EGFR-TKI resistance in EGFR mutant lung cancer in Japanese patients.
|
22052230 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The effects of E7050 on HGF-induced resistance to reversible (gefitinib), irreversible (BIBW2992), and mutant-selective (WZ4002) EGFR-TKIs were determined using the EGFR mutant human lung cancer cell lines PC-9 and HCC827 with an exon 19 deletion and H1975 with an T790M secondary mutation.
|
22317763 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The three major clinically relevant mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant lung cancer are a second mutation in the EGFR gene (T790M), Met amplification, and increased expression of hepatocyte growth factor (HGF).
|
22592212 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation.
|
22751098 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
|
22899358 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation.
|
23045273 |
2013 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
|
23185274 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, knock-down of T790M transcript by siRNAs further decreases the cell growth of T790M mutant lung cancer cells that are treated with TKIs or cetuximab.
|
23266614 |
2013 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.
|
23588221 |
2013 |